Ceri Bygrave

Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients

Rosemary A. Barnes, P. Lewis White, Ceri Bygrave et al. · Journal of Clinical Pathology · 2008 · 91 citations

Medicine, Hematology, Infectious Diseases +17

Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma

Ceri Bygrave, Charlotte Pawlyn, Faith E. Davies et al. · British Journal of Haematology · 2020 · 51 citations · Full text

Medicine, Oncology, Cell Therapy +12

Risk of relapse of multiple myeloma following kidney transplantation

Sapna Shah, Maria Ibrahim, Michael P. Delaney et al. · Clinical Kidney Journal · 2018 · 26 citations · Full text

Medicine, Nephrology, Oncology +13

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial

Kwee Yong, William Wilson, Ruth M. de Tute et al. · The Lancet Haematology · 2022 · 24 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial

Kara‐Louise Royle, Amy Beth Coulson, Karthik Ramasamy et al. · BMJ Open · 2022 · 16 citations · Full text

Medicine, Oncology, Pharmacotherapy +17